Skip to main content
CHEOY logo

Cochlear Limited (CHEOY) Stock: Price, Forecast & Analyst Target

Cochlear Limited (CHEOY) — price $50.73 (-0.51%), as of the Nov 19, 2026 trading session; market cap $6.64B.

Educational signal · not a buy or sell recommendation · How to read this

$50.73 −$0.26 (-0.51%) Market Cap $6.64B

Cochlear Limited · CHEOY · Healthcare · Medical - Devices

Cochlear Limited is a global healthcare company specializing in advanced auditory solutions. It develops and manufactures surgically implanted hearing devices for individuals of all ages, from children to adults, across the world.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • LIVN · LivaNova PLC · 88 /100
  • GMED · Globus Medical, Inc. · 94 /100
  • BRKR · Bruker Corporation · 59 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$50.73
Change on the day-0.51%
52-week range$31.82–$98.29
Market capitalisation$6.64B
Price / earnings (trailing)67.75
Shares traded on the day100
Beta (volatility vs the S&P 500)0.26

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $34, high $95, latest $51. $95 $34 high $95 Oct 17, 2025 Nov 19, 2026 · $51 $93Oct 17, 2025$94Oct 31, 2025$90Nov 14, 2025$92Nov 28, 2025$88Dec 12, 2025$88Dec 26, 2025$88Jan 9, 2026$95Jan 23, 2026$90Feb 6, 2026$70Feb 20, 2026$62Mar 6, 2026$57Mar 20, 2026$61Apr 2, 2026$61Apr 17, 2026$35May 1, 2026$34May 15, 2026$36May 29, 2026$37Jun 12, 2026$41Jun 26, 2026$42Jul 10, 2026$39Jul 24, 2026$44Aug 7, 2026$49Aug 21, 2026$51Sep 4, 2026$47Sep 18, 2026$44Oct 2, 2026$45Oct 16, 2026$50Oct 30, 2026$51Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Cochlear (CHEOY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Weak
Debt/Equity Moderate
ROE Moderate
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Cochlear (CHEOY), and what does it report?

Short answer · as of

Cochlear Limited is a global healthcare company specializing in advanced auditory solutions. It develops and manufactures surgically implanted hearing devices for individuals of all ages, from children to adults, across the world. Healthcare / Medical Devices Headquarters: 1 University Avenue, Sydney, NSW, 2109, AU. It employs 5,400 people and is led by Diggory William Howitt. In Q4 FY2026 it reported revenue of A$1.18B and net income of -A$14M. The market values it at $6.64B.

2 · Latest results

What do the latest results show for Cochlear (CHEOY)?

Short answer · as of

The most recent reported quarter, Q4 FY2026, carried revenue of A$1.18B.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2026A$1.18B-A$14M-A$0.11 (diluted)
Q2 FY2026A$1.15BA$159MA$1.22 (diluted)
Q4 FY2025A$1.19BA$184MA$1.40 (diluted)
Q2 FY2025A$1.17BA$205MA$1.56 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Cochlear (CHEOY)?

Short answer · as of

The distress and quality screens read Altman Z 8.79 · Piotroski F 5. Trailing ratios: ROE 8.0% · ROA 5.7% · current ratio 2.15 · earnings yield 1.5% · free-cash-flow yield 3.0%.

4 · What to check next?

What should you watch next at Cochlear (CHEOY)?

Short answer · as of

Current published price targets run low $117.00 · high $117.00 · consensus $117.00 · median $117.00 against a quoted price of $50.73 (as of Nov 19, 2026).

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$117.00 – $117.00
Consensus target
$117.00
Median target
$117.00

Consensus record · Captured .

Measured against a quoted price of $50.73 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CHEOY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CHEOY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Cochlear (CHEOY)?

Read these with our analysis →

Common Questions About CHEOY (Healthcare)

These answers are editorial: 1 of these 8 answers is drawn from the CHEOY research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is CHEOY a good stock to buy?

Stock Expert AI does not rate CHEOY buy, sell or hold. Cochlear Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CHEOY stock price today?

The last price recorded for Cochlear Limited (CHEOY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the CHEOY price target?

The analyst consensus price target for Cochlear Limited (CHEOY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What does Cochlear Limited do?

Cochlear Limited specializes in providing implantable hearing solutions, primarily cochlear implants and bone conduction systems. These devices are designed to restore or improve hearing for individuals with varying degrees of hearing loss, from severe to profound.

What are the key factors to evaluate for CHEOY?

Evaluate CHEOY on fundamentals, analyst consensus, and risk factors. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. This focus on innovation will help Cochlear maintain its competitive edge and drive long-term growth. Not financial advice.

How frequently does CHEOY data refresh on this page?

CHEOY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CHEOY's recent stock price performance?

Cochlear Limited (CHEOY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Global leader in implantable hearing solutions. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CHEOY overvalued or undervalued right now?

The trailing P/E of Cochlear Limited (CHEOY) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 23 figures on this page — 20 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.